30 closest matches · ranked by relevance
Hepatitis
Primary: Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period — 0.0; 6.9; 0.3; 0.1 Percent of Participants
Hepatitis E · Immunisation
Primary: Number of Participants With Solicited Local Reactogenicity Events — 11; 3; 17; 1 Participants
Hepatitis E
Primary: Number of Participants Whose Anti-HEV Antibody Seroconverted at One Month After The Third Dose — 188; 196 Participants
Hepatitis B
Primary: Percentage of Subjects With Seroprotective Immune Response — 95.1; 81.3 Percentage of Participants
Hepatitis B, Chronic
Primary: Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss — 39; 40; 70 Participants — p=0.860
Chronic Hepatitis B
Primary: Number of Participants Achieving HBV DNA ≤300 Copies/mL at Week 104 — 85; 403 participants
Breast Cancer · Hepatitis C
Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027
Hepatitis B
Primary: Serum Hepatitis B Surface Antigen Completion — 389; 177 Participants
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
Hepatitis B
Primary: Number of Participants With an Adverse Event — 74 participants
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
Chronic Hepatitis B
Primary: Percentage of Participants Who Achieved a Virologic Response at Week 24 — 92.86; 67.19 Percentage of participants — p=0.0006
Chronic Hepatitis B
Primary: Proportion of Patients With HBsAg Response at 12 Week of Therapy — 0; 0; 1; 0 Participants
Hepatitis B
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 9; 3; 7; 7 Participants
Hepatitis B, Chronic
Primary: Number of Hepatitis B Envelope Antigen (HBeAg) Positive Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Less Than (<) 1,00,000 Copies Per Milliliter…
Hepatitis B
Primary: Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24 — -4.48; -3.40 log10 copies/mL — p=<0.0001
Hepatitis C
Primary: Point Prevalence of Hepatitis C Infection — 9 percentage of total subjects
Chronic Hepatitis c
Primary: Sustained Virologic Response — 24; 25 participants
Hepatitis B, Chronic
Primary: Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL) — 7 participants
Chronic Hepatitis B
Primary: Number of Participants With Adjudicated Overall Malignant Neoplasms — 331; 337 Participants — p=0.3553
Hepatitis B, Chronic
Primary: Percentage of Participants Who Achieved 0.25 Logarithm to the Base 10 (Log10) Hepatitis B Surface Antigen (HBsAg) Reduction From the Baseline at Week 48 — 4; 96…
Hepatitis B
Primary: Seroconversion Rate — 47; 46 Participants — p=1
Hepatitis B, Chronic
Primary: Percentage of Participants Achieving Hepatitis C Virus Deoxyribonucleic Acid <10,000 Copies/Milliliter at Week 72 — 65.4 Percentage of participants
Hepatitis B
Primary: Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection — 90.1; 82.5 Percentage of participants
Healthy
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
Hepatitis C
Primary: Number of Participants With Sustained Virological Response (SVR) — 49 Participants
HIV Infection · Hepatitis B
Primary: Percentage of Participants With Primary Seroprotection Response — 93.1; 99.4; 80.6; 100 percentage of participants
Escherichia Coli Diarrhea
Primary: Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum Severity — 15; 14; 15; 15 Participants
Hepatitis D
Primary: Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy. — -0.13; -0.73; -1.54 log(IU/ml) — p=0.03
Hepatitis B
Primary: Percentage of Participants With Local and Systemic Post-injection Reaction Rates — 38.2; 37.9; 37.2; 33.0 percentage of subjects